Sensorion SA - Asset Resilience Ratio
Sensorion SA (ALSEN) has an Asset Resilience Ratio of 14.20% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read how much debt does Sensorion SA carry for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2016–2024)
This chart shows how Sensorion SA's Asset Resilience Ratio has changed over time. See ALSEN net assets for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Sensorion SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Sensorion SA worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €10.42 Million | 14.2% |
| Total Liquid Assets | €10.42 Million | 14.20% |
Asset Resilience Insights
- Moderate Liquidity: Sensorion SA has 14.20% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Sensorion SA Industry Peers by Asset Resilience Ratio
Compare Sensorion SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233 |
Biotechnology | 0.02% |
|
Staidson Beijing Biopharma
SHE:300204 |
Biotechnology | 7.93% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 41.25% |
|
Ardelyx Inc
NASDAQ:ARDX |
Biotechnology | 41.14% |
|
Xiangxue Pharmaceutical
SHE:300147 |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Sensorion SA (2016–2024)
The table below shows the annual Asset Resilience Ratio data for Sensorion SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 69.64% | €62.18 Million ≈ $72.69 Million |
€89.28 Million ≈ $104.37 Million |
+34.24pp |
| 2020-12-31 | 35.41% | €24.03 Million ≈ $28.09 Million |
€67.87 Million ≈ $79.35 Million |
+9.15pp |
| 2019-12-31 | 26.25% | €10.00 Million ≈ $11.69 Million |
€38.09 Million ≈ $44.53 Million |
+26.08pp |
| 2018-12-31 | 0.17% | €16.00K ≈ $18.71K |
€9.47 Million ≈ $11.07 Million |
-85.87pp |
| 2017-12-31 | 86.04% | €9.60 Million ≈ $11.23 Million |
€11.16 Million ≈ $13.05 Million |
+14.10pp |
| 2016-12-31 | 71.94% | €8.53 Million ≈ $9.97 Million |
€11.85 Million ≈ $13.86 Million |
-- |
About Sensorion SA
Sensorion SA, a biotechnology company, develops drug candidates for the treatment of inner ear disorders in France. The company's product portfolio includes SENS-401 SSNHL, which has completed Phase 2b clinical trial for the treatment of Sudden Sensorineural Hearing Loss; SENS-401 CIO that is in Phase 2a clinical trial for the treatment of Cisplatin-Induced Ototoxicity; and SENS-401 Cochlear, whi… Read more